Yisuishengxue Granule
PreclinicalSmall molecule
Yisuishengxue Granule is one of 27 small molecule programs targeting Thalassemia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Thalassemia
#DrugCompanyPhaseTrials
1Exjade
NovartisApproved
Reblozyl
Bristol-Myers SquibbApproved
Thalomid
Bristol-Myers SquibbApproved
Cellcept
RocheApproved
Desferal
Jazz PharmaceuticalsApproved
Trexall
Jazz PharmaceuticalsApproved
Fludara
SanofiApproved
Simulect
NovartisApproved
Zometa
PfizerApproved
Prograf
VVeloxis Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Thalassemia1 trial
Study of Effects of YisuiShengxueGranules on Thalassemia
Completed·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences··NCT01549080·2 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yisuishengxue Granule. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details